Patients who experience rapid dose escalation may be more prone to fatigue and gastrointestinal symptoms
The long-term dosing strategy should be planned from the beginning, not decided after reaching a weight loss goal
Neuropsychopharmacology 44, 20542064
A central highlight includes the highly anticipated Phase 3 results from the REIMAGINE 1, 2, and 3 clinical trials evaluating CagriSema, a novel fixed-dose combination of the amylin analogue cagrilintide and the GLP-1 receptor agonist semaglutide
Cultural Awareness and Marketing: High-profile media attention, celebrity endorsement, and powerful direct-to-consumer (DTC) marketing have brought GLP-1s into the public consciousness
Results from recent trials have demonstrated notably greater reductions in body weight, as illustrated below in the SURMOUNT-3 Phase 3 trial with 25% weight reduction among subjects with GLP-1/GIP and engaged in intensive lifestyle intervention